- Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
-
Lim SM, Hong MH, Kim HR
- KMID: 2471050
- Immune Netw.
- 2020 Feb;20(1):e10.
- doi: 10.4110/in.2020.20.e10
Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
-
Kim T, Cha YJ, Chang YS
- KMID: 2466620
- Tuberc Respir Dis.
- 2020 Jan;83(1):51-60.
- doi: 10.4046/trd.2019.0026
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)—22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1... -
- CITED
-
- Close
- SHARE
-
- Close
- A Man Presenting with Sudden Weakness and Pain of the Right Hand, by Non-Small Cell Lung Cancer with Brain Metastases
-
Sung WJ, Hong BY, Kim JS, Yoo JW, Lim SH
- KMID: 2470353
- Clin Pain.
- 2019 Dec;18(2):88-91.
- doi: 10.35827/cp.2019.18.2.88
Unexplained pain and weakness, i.e., without obvious predisposing factors, are often encountered by physiatrists and efforts should be made to determine the cause. A 63-year-old male presented with radiating pain... -
- CITED
-
- Close
- SHARE
-
- Close
- Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
-
Jeong I, Song J, Bae SY, Lee SK
- KMID: 2468811
- J Cancer Prev.
- 2019 Dec;24(4):217-223.
- doi: 10.15430/JCP.2019.24.4.217
BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies... -
- CITED
-
- Close
- SHARE
-
- Close
- Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
-
Chang S, Park HK, Choi YL, Jang SJ, Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists
- KMID: 2465433
- J Pathol Transl Med.
- 2019 Nov;53(6):347-353.
- doi: 10.4132/jptm.2019.09.29
BACKGROUND: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1)... -
- CITED
-
- Close
- SHARE
-
- Close
- Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer
-
Lee JM, Kim T, Kim EY, Kim A, Lee DK, Kwon NH, Kim S, Chang YS
- KMID: 2460216
- Yonsei Med J.
- 2019 Nov;60(11):1005-1012.
- doi: 10.3349/ymj.2019.60.11.1005
PURPOSE: Identification of lymph node (LN) metastasis in non-small cell lung cancer (NSCLC) is critical for disease staging and selection of therapeutic modalities. Sometimes it is not possible to obtain... -
- CITED
-
- Close
- SHARE
-
- Close
- Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer
-
Kim KM, Lee SH, Kim SM, Kim NY, Gwak HS, Shin SH, Kwon JW, Yoo H
- KMID: 2461187
- Brain Tumor Res Treat.
- 2019 Oct;7(2):137-140.
- doi: 10.14791/btrt.2019.7.e44
BACKGROUND: The aim of this study was to compare epidermal growth factor receptor (EGFR) mutations between non-small cell lung cancer (NSCLC) and corresponding brain metastases (BMs) in Korea society. METHODS: From... -
- CITED
-
- Close
- SHARE
-
- Close
- Demographic and Socioeconomic Factors for Renouncing Further Active Therapy for Patients with Brain Metastasis of Non-Small Cell Lung Cancer
-
Jung G, Kim SH, Kim TG, Kim YZ
- KMID: 2461184
- Brain Tumor Res Treat.
- 2019 Oct;7(2):112-121.
- doi: 10.14791/btrt.2019.7.e35
BACKGROUND: As patients with brain metastasis (BM) of non-small cell lung cancer (NSCLC) have dismal prognosis, some of them decide to discontinue further treatment for BM. The objective of this... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
-
Park EY, Kim YS, Choi KH, Song JH, Lee HC, Hong SH, Kang JH
- KMID: 2460741
- Radiat Oncol J.
- 2019 Sep;37(3):166-175.
- doi: 10.3857/roj.2019.00220
PURPOSE: This study aimed to investigate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors in patients with locally advanced non-small cell lung cancer (NSCLC) who received concurrent chemoradiotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Local ablative radiotherapy for oligometastatic non-small cell lung cancer
-
Suh YG, Cho J
- KMID: 2460739
- Radiat Oncol J.
- 2019 Sep;37(3):149-155.
- doi: 10.3857/roj.2019.00514
In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
-
Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS
- KMID: 2457035
- Korean J Intern Med.
- 2019 Sep;34(5):1116-1124.
- doi: 10.3904/kjim.2018.011
BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of... -
- CITED
-
- Close
- SHARE
-
- Close
- Preoperative Risk Factors for Pathologic N2 Metastasis in Positron Emission Tomography-Computed Tomography–Diagnosed N0–1 Non-Small Cell Lung Cancer
-
Yoon TH, Lee CH, Park KS, Bae CH, Cho JW, Jang JS
- KMID: 2455147
- Korean J Thorac Cardiovasc Surg.
- 2019 Aug;52(4):221-226.
- doi: 10.5090/kjtcs.2019.52.4.221
BACKGROUND: Accurate mediastinal lymph node staging is vital for the optimal therapy and prognostication of patients with lung cancer. This study aimed to determine the preoperative risk factors for pN2... -
- CITED
-
- Close
- SHARE
-
- Close
- A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer
-
Lim TY, Park S, Kang CH
- KMID: 2455145
- Korean J Thorac Cardiovasc Surg.
- 2019 Aug;52(4):195-204.
- doi: 10.5090/kjtcs.2019.52.4.195
Lobectomy is considered the standard strategy for early-stage non-small cell lung cancer (NSCLC). However, sublobar resection for NSCLC has recently received increased attention. The objective of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between Expression of 8-OHdG and Cigarette Smoking in Non-small Cell Lung Cancer
-
An AR, Kim KM, Park HS, Jang KY, Moon WS, Kang MJ, Lee YC, Kim JH, Chae HJ, Chung MJ
- KMID: 2454601
- J Pathol Transl Med.
- 2019 Jul;53(4):217-224.
- doi: 10.4132/jptm.2019.02.20
BACKGROUND: Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes,... -
- CITED
-
- Close
- SHARE
-
- Close
- PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
-
Kim H, Chung JH
- KMID: 2454598
- J Pathol Transl Med.
- 2019 Jul;53(4):199-206.
- doi: 10.4132/jptm.2019.04.24
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
-
Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS
- KMID: 2454300
- Cancer Res Treat.
- 2019 Jul;51(3):1086-1097.
- doi: 10.4143/crt.2018.537
PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression... -
- CITED
-
- Close
- SHARE
-
- Close
- Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study
-
Chung E, Noh JM, Lee KC, Kim JH, Chung WK, Suh YG, Lee JA, Seol KH, Wu HG, Kim YS, Noh OK, Park JW, Lee DS, Lee J, Kim YS, Park WY, Kang MK, Jo S, Ahn YC
- KMID: 2454292
- Cancer Res Treat.
- 2019 Jul;51(3):1001-1010.
- doi: 10.4143/crt.2018.415
PURPOSE: Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB)... -
- CITED
-
- Close
- SHARE
-
- Close
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
-
Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS
- KMID: 2454287
- Cancer Res Treat.
- 2019 Jul;51(3):951-962.
- doi: 10.4143/crt.2018.052
PURPOSE: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Factors in Stage IIB Non-Small Cell Lung Cancer according to the 8th Edition of TNM Staging System
-
Shin JW, Cho DG, Choi SY, Park JK, Lee KY, Moon Y
- KMID: 2455156
- Korean J Thorac Cardiovasc Surg.
- 2019 Jun;52(3):131-140.
- doi: 10.5090/kjtcs.2019.52.3.131
BACKGROUND: The purposes of this study were to evaluate the appropriateness of the stage migration of stage IIA non-small cell lung cancer (NSCLC) in the seventh edition of the tumor,... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
-
Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC
- KMID: 2446957
- Yonsei Med J.
- 2019 Jun;60(6):525-534.
- doi: 10.3349/ymj.2019.60.6.525
PURPOSE: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and... -
- CITED
-
- Close
- SHARE
-
- Close
